Replies to post #26460 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC ..GARZA TIME.....The agreement can be cancelled by Uni and/or AMDL Diagnostics Inc after the last patent expires or by AMDL Dx if Uni sales quota are not met... Only if Uni terminates the agreement, which they did not do, or we would have had a SEC filing before the company was voluntarily revoked by Mac on July 3, 2014.This was after the last patent..The agreement with Uni and AMDL Diagnostics Inc. a Division of Radient Pharmaceuticals with Mac as President and Akio as Secretary..Is still in force...Wolf

Here are the results from the study below, GCDX/PDX Presentation, and LC Setinel (2010)

Published February 13, 2013 Independent study...
high Sensitivity (95.8%) and specificity (91.9%).

The results from William Gartner GCDX/PDX presentation
Women ROC 97 Sensitivity 89 Specificity 95
Men ROC 98 Sensitivity 92 Specificity 95

LC Sentinel
ROC......97 Sensitivity 87 Specificity; 95

Amazing how the results are similar you understand...See you in New York City. DC for our first stockholders' meeting....Wolf


http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm

"The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests, or if UNI does not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters. Each party has the right to terminate the Agreement in certain circumstances, including a material breach under the Agreement or following a cure period associated with a government imposed prohibition against the sale of the licensed products."



"A new independent scientific study published in the Oncogenesis, Inflammatory and Parasitic Tropical Diseases of the Lung edited by Jean-Marie Kayembe, ISBN 978-953-51-0982-2, published February 13, 2013, indicated that Onko-Sure® itself might contribute to confirm tumor diagnosis and to identify patients with advanced lung cancer, with high sensitivity (95.8%) and specificity (91.9%). This new data strengthens our views that Onko-Sure® can be used as a lung cancer screening tool."

******************************************************************

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista's efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S.